Abstract: Liu Junlin, Zeng Huiming, Lin Min′ge, Ju Mei, Wu Zhiming, Li Meijiao, Li Yuyang, Yin Mei Department of Dermatology and Venereology, The Second Affiliated Hospital of Hainan Medical University, Haikou 570311, China（Liu JL）; Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou 570311, China（Wu ZM）; Health Examination Center, The Second Affiliated Hospital of Hainan Medical University, Haikou 570311, China（Yin M）; Department of Dermatology and Venereology, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, China（Zeng HM, Lin MG）; Department of Physical Therapy, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China （Ju M）; Department of Dermatology and Venereology, Chinese Medicine Hospital of Hainan Province, Haikou 570203, China（Li MJ）; Department of Dermatology and Venereology, The Third People′s Hospital of Hainan Province, Sanya 572000, China（Li YY） Corresponding author: Liu Junlin, Email: liujunlin0759@163.com 【Abstract】 Objective To investigate association of vitamin D receptor （VDR） polymorphisms with susceptibility to psoriasis vulgaris and clinical response to calcipotriol in patients with psoriasis vulgaris. Methods A total of 110 patients with psoriasis vulgaris and 183 healthy controls were enrolled into this study, and they were all of Han nationality from Hainan province. Ligase detection reaction （LDR） was conducted to determine the genotypes of VDR gene polymorphisms rs2228570, rs731236, rs1544410 and rs7975232. Single nucleotide polymorphism （SNP）-based association analysis in genotypic and allelic models, and haplotype-based association analysis were then performed. Then, 75 patients with psoriasis area and severity index （PASI） scores less than 10 were topically treated with calcipotriol ointment alone. After 6-week treatment, the efficacy of calcipotriol ointment was evaluated, and the correlation between the efficacy and individual genotypes was analyzed. Results The frequency of A allele of rs7975232 in the psoriasis group and control group was 39.09% and 27.05% respectively, and the risk of developing psoriasis in rs7975232 A allele carriers was significantly higher than that in non-carriers （OR = 1.731, 95% CI: 1.213 - 2.471, P < 0.05）. Additionally, the risk of developing psoriasis in individuals with AA genotype （OR = 2.404, 95% CI: 1.085 - 5.328, P < 0.05）, as well as in individuals with AC genotype （OR = 2.143, 95% CI: 1.283 - 3.579, P < 0.05）, was significantly higher than that in patients with CC genotype. CTGA haplotype carriers （rs2228570, rs731236, rs1544410, rs7975232, respectively） had significantly higher risk of developing psoriasis compared with non-carriers （OR = 1.907, 95% CI: 1.132 - 3.214, P < 0.05）. Among 72 patients with mild-to-moderate psoriasis whose PASI scores were less than 10, patients with CC genotype of rs7975232 showed better response to calcipotriol ointment compared with those with AC genotype （OR = 3.798, 95% CI: 1.061 - 13.590, P < 0.05） and those with AA genotype （OR = 9.667, 95% CI: 1.556 - 60.040, P < 0.05）. Conclusion VDR polymorphisms are associated with psoriasis susceptibility and clinical response to calcipotriol in patients with psoriasis individuals.